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ABSTRACT-Between January, 1975, and December, 1984, at the University of Michigan Medical 
Center, 17 boys with leukemia presented with overt or occult isolated testicular relapse. Diagnosis 
was obtained by bilateral open-wedge biopsies of the testes. Al1 the patients were treated with 
combined local testicular irradiation and systemic chemotherapy. In only 1 of the 17 patients (6 %o) 
testicular leukemia developed as the only site of relapse. It appears that doses in the range of 2,000 
to 2,400 cGy in 10 to 12 fractions achieve optimum control of leukemie infiltration of the testes. 
Acute lymphoblastic leukemia (ALL) is the 
most common cancer and the second leading 
cause of death in children under fifteen years of 
age.’ About 85 per cent of the children who sur- 
vive three to five years without having a bone 
marrow or extramedullary relapse wil1 remain 
in prolonged remission and may be considered 
curede2 
Isolated relapse in extramedullary sites often 
precedes bone marrow relapse. The median 
survival after isolated relapse is about ten 
months for bone marrow, eighteen months for 
testes, and twenty months for centra1 nervous 
system (CNS), respectively 3 Isolated testicular 
relapse is replacing the CNS as the major site of 
extramedullary relapse. It has been reported in 
14.8 per cent of boys under treatment4 and in as 
high as 41 per cent of boys in whom main- 
tenance therapy was stopped after three or 
more years of continuous complete remission.5 
Occult testicular leukemia was detected by 
elective bilateral open-wedge biopsies in 5 of 59 
(8.5 % ) boys in continuous complete remission 
for three years, as reported by Askin et al.6 
Radiation is the preferred method of treat- 
ment for testicular relapse; however, the opti- 
mal dose to achieve maximum local control of 
leukemie testicular infiltrates with minima1 tis- 
sue damage has not been individualized. Be- 
cause new chemotherapeutic protocols are in- 
creasing the numbers of patients achieving 
remission, this information is of even greater 
relevante. 
Material and Methods 
From January, 1975, to December, 1984, 17 
boys with the diagnosis of ALL received testicu- 
lar irradiation for extramedullary relapse at the 
University of Michigan Hospital. Their ages 
ranged from ten months to seventeen years 
(average of 6.5 years) (Table 1). Patients were 
treated with systemic chemotherapy as per 
Children’s Cancer Study Group Protocols. 
They also received prophylactic cranial irradia- 
tion. Five of 17 patients had occult testicular 
leukemia, and 12 had overt testicular leukemia 
at the completion of three years of maintenance 
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TABLE 1. ALLhesticular leukemia 
Age (Yrs) Dx (Yr) 
Testicular RTIField 






































































































KEY: NED = no evidente of disease; DOD = dead of disease; BM = bone marrow; Fx = fraction: Bx - biopsy. 
chemotherapy. In al1 patients the diagnosis was 
obtained by bilateral open-wedge biopsies. 
Al1 these children received systemic chemo- 
therapy and local radiation therapy to the 
testes. Both testes were treated using an ante- 
rior portal only. Both testicles were treated be- 
cause of the high incidence of occult involve- 
ment in the clinically normal contralateral 
testicle. Field sizes were 5 x 5 cm to 7 x 7 cm. 
Dosages were 1,800 cGy in 1 patient, 2,000 cGy 
in 4, 2,400 cGy in 11, and 3,000 cGy in 1 pa- 
tient, delivered in two to three weeks. Cobalt- 
60 was used in 5 patients, orthovoltage (250 kV) 
in 5 patients, and appropriate electron-beam 
energy in the remaining 7 patients. 
Results 
Seven of the 17 boys are long-term survivors 
(Table 1). Five of them are in complete remis- 
sion three to six years post-therapy, with an 
average of 3.4 years. One child is undergoing 
systemic chemotherapy for bone marrow re- 
lapse without evidente of testicular leukemia. 
In only one of the survivors has post-irradiation 
testicular relapse developed. He underwent or- 
chiectomy and is alive and wel1 at the time of 
this writing. The remaining 10 patients died of 
leukemia or leukemia-related problems. None 
of them had evidente of testicular involvement 
at death. Half of them were documented to be 
free of testicular leukemia at autopsy examina- 
tion, the rest had clinically benign testes. 
Side effects related to radiation therapy were 
moderate skin erythema and subsequent scrotal 
cutaneous pigmentation in al1 boys. In only one 
child gonadal failure developed and replace- 
ment hormonal therapy is being given. This 
child received radiation therapy by 
orthovoltage equipment. 
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Comment 
Leukemie infiltration of the testes in acute 
lymphoblastic leukemia is a late complication 
that is being seen more often due to the dra- 
matic improvements in survival with more ef- 
fective chemotherapeutic regimens. Extrame- 
dullary isolated relapse is most commonly seen 
in the CNS and in the testes. Several hypotheses 
have been formulated to explain this occur- 
rente. It has been suggested that the testes may 
be acting as a sanctuary site similar to the CNS 
where leukemie cells are protected by some sort 
of tissue barrier from the systemic chemother- 
apy.’ Another explanation for this leukemie 
infiltration has been related to the lower 
temperature of the testes, which could reduce 
the susceptibility of these cells to cytotoxic 
drugs.8 
Radiation therapy has been the treatment of 
choice for testicular relapse in leukemia and has 
produced excellent results both with local dis- 
ease control and long-term survival.e Although 
leukemie infiltrates are relatively radiosensi- 
tive, this appears to vary with the body site. 
The optimum dose of radiation therapy to the 
testes has not been established. This is due to 
the smal1 number of patients with testicular re- 
lapse and the variability in treatment modality 
and total dosage used. There is also a lack of 
uniform criteria for determining the diagnosis 
with some series using only clinical findings of 
testicular enlargement. 
D’Angio, Evans, and MituslO using doses of 
1,400 cGy in two weeks obtained good re- 
sponses when treating leukemie infiltrates. To- 
tal doses between 2,000-2,500 cGy are recom- 
mended by Atkinson et al. l1 for patients when a 
long survival is expected. 
Steinfeld12 gave 600-900 cGy to 6 patients 
with control of disease in 4 and failure in 2. La- 
ter he treated the patients who failed with addi- 
tionall,400 cGy and 3,500 cGy to achieve local 
control. Mirro et ~1.‘~ reported 1 patient had 
persistent disease after 2,600 cGy in 13 frac- 
tions of 200 cGy each. They also found that 
regression of testicular leukemia is slow after 
therapy. 
Our series, although small, is homogeneous 
regarding diagnosis, mode of therapy and total 
dose, al1 patients receiving treatment at the 
same institution. Our results regarding local 
control are highly encouraging. Only in 1 of 17 
boys (6%) did local failure without any evi- 
dence of systemic leukemia develop. The doses 
given were in a range of 2,000 to 2,400 cGy in 
most patients,14 and minima1 complications 
were encountered. None of the boys treated 
with modern equipment had endocrine gonadal 
failure. The only patient in whom gonadal 
failure developed was a child treated with 
orthovoltage equipment. At present al1 patients 
should receive radiation therapy delivered by 
megavoltage equipment. 
Due to the low incidence of testicular leuke- 
mia, prophylactic irradiation is not recom- 
mendedae Orchiectomy should not be consid- 
ered the primary treatment for testicular 
leukemia, since radiation is equally effective in 
achieving local control and is less mutilating 
without the negative psychologie impact of or- 
chiectomy.15 Also, it appears that the risk of go- 
nadal failure from radiation is minima1 when 
adequate doses are used. Endocrine gonadal in- 
sufficiency could develop in leukemie patients 
for a variety of reasons, for example, CNS irra- 
diation, systemic chemotherapy, and direct tes- 
ticular irradiationl4 Results of studies based on 
basal plasma gonadotropin and testosterone 
levels have led to the conclusion that prepuber- 
tal irradiation of the human testes with doses up 
to 3,000 rad delivered directly does not produce 
clear evidente of damage.14 This has been re- 
cently challenged by Brauner et al. le who found 
testosterone insufficiency a frequent complica- 
tion of testicular irradiation. However, its 
severity appeared to be variable and probably 
was related to the time elapsed since radiation. 
Some patients could even maintain a compen- 
sated Leydig-cel1 insufficiency for a long 
enough period to allow an appropriate progres- 
sion of virilization , 
The importante of careful long-term follow- 
up in predicting the course of puberty and de- 
termining the need for testosterone replacement 
therapy is apparent. l7 
In summary, we believe that radiation 
therapy is the modality of choice for testicular 
leukemia. Due to the high frequency of bilat- 
era1 involvement,6 bilateral testicular irradia- 
tion is required. Occasionally resistance to ra- 
diation may occur, and it was seen in 6 per cent 
of patients in our series. In the absente of sys- 
temic disease, reseeding of the testes is unlikely. 
Megavoltage equipment with either e°Co or 
preferably with appropriate electron-beam 
energy should be utilized. Total doses of 2,400 
in 12 fractions of 200 cGy appear to be satisfac- 
tory, with minima1 side effects and excellent lo- 
cal control (94 % ) , 
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